A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Eyetech Pharmaceuticals1,000 enrolled

Overview

The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,000

Conditions

Age-Related Macular Degeneration (AMD)

Interventions

pegaptanib sodium (Macugen)DRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subfoveal CNV secondary to AMD * At least 1 but not more than 3 prior treatments for AMD Exclusion Criteria: * Subfoveal scar or subfoveal atrophy * Significant media opacities, including cataract, which might interfere with visual acuity

Locations (1)

Retina Research Institute of Texas, LLC

Abilene, Texas, United States

RECRUITING

Central Contacts

Macugen Information

CONTACT

1-866-622-8436

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.